A New Dawn for
Starve Tumors, Nourish the Body
Tality is a revolutionary food product under clinical investigation for the treatment of cancer.
Filtricine, Inc. is a clinical stage biotechnology company focused on developing novel products for cancer care. We are backed by venture capital and located in the San Francisco Bay Area of California. We are developing an innovative way to help patients treat their cancers through our proprietary nutritional regimen of replacement meals. Our lead product is currently being investigated in clinical studies.
Food as Medicine
Our founders discovered Targeted Nutrients Deprivation during their research at Stanford University. Cancer cells need multiple non-essential amino acids to survive. Those NEAAs are found in all foods we eat. We found a way to formulate foods without these NEAAs while preserving the nutrients our bodies need to thrive. Tality was created for cancer patients to regain control of their lives and get back to living their best life.
Clinical Trial Results
Filtricine is sponsoring a clinical trial in prostate cancer patients at Stanford University School of Medicine. Early clinical study results show Tality is nutritionally complete and safe. “Three (out of ten) participants experienced decrease in PSA (prostate-specific antigen). One participant experienced 32% decrease from baseline level of 107.9.” This clinical trial is ongoing. Tality is available to prostate cancer patients through this trial. Read Poster Here.
Prostate cancer patients?
You are welcome to join this ongoing clinical trial at Stanford University
Other cancer patients?
Tality is open to all cancer patients willing to try it for 4 weeks at no cost